Skip to content
Navigate to homepage - Cerba Research


Discover the diversity of our genomics sequencing and testing services, tailored for your project. Get in touch with our team today for more information.

Over 30 years of experience in genomics

Since 1992, Cerba Research and Cerba Healthcare have pioneered the art of human genetic testing, as we were the first laboratory in Europe to introduce genetic testing.

Thanks to this experience, we are able to collaborate with the life science community to provide the most suitable genomic services and enhance the power of your genetic material.

Cerba Research can work with you to select the most suitable platform and assay to reach your project expectations.

Our Genomics Solutions

people icon


Specialized Technicians

people icon



map pin icon

25 000


Our Genomics Landscape

Discover the diversity of our genomics platform, tailored for your project

Next Generation Sequencing

● Single nucleotide variants (SNV)
● Insertion and deletions (numerous broad panel assays aligned with guidelines)
● Copy number variations (CNV)
● Gene fusions
● Tumor mutational burden (TMB)
● Microsatellite instability (MSI)
● Minimal residual disease (MRD) on demand
● Homologous recombination deficiency (HRD)
● Somatic hypermutation


Cerba Research’s family of qPCR solutions is designed to simplify your process and expedite your clinical trial results and to help you answer important clinical questions faster and easier. For example, we can detect EGFR alterations by means of FFPE and ctDNA using qPCR instruments.

dd (Digital Droplet) PCR

Cerba Research also owns droplet digital (ddPCR) instruments. ddPCR is a method that can perform digital PCR which is based on water-oil emulsion droplet technique. ddPCR may also offer a robust mutation detection sensitivity (0.05-0.1%).

miRNA analysis

Analyses of miRNA are carried out with protocols similar to those utilized for protein-encoding genes. The artificial up-regulation of miRNAs can aid in identifying gain-of-function phenotypes, and the down-regulation can be carried out to determine loss-of-function phenotypes. Combining both up- and down-regulation can help identify cellular processes and genes that are controlled by specific miRNAs.

TCR Sequencing

The TCR repertoire, that is, the diverse collection of clonotypes in an organism, plays an important role in shaping the immune function, health, and disease progression. At Cerba Research, we are able to perform TCR seq by means of NGS with various already existing and validated kits.

Nanostring Assay

Nanostring is an amplification-free technology that measures nucleic acid content by counting molecules directly. It enables researchers to analyze and interpret differential gene expression results and benefit from a solution for multiplex analysis of 800+ targets.

Whole Exome / Genome Sequencing

Cerba Research is proud to propose whole exome and whole genome sequencing capabilities, including coding, non-coding and mitochondrial DNA.

We can also help you discover novel genomic variants (structural, single nucleotide, insertion-deletion, copy number) and previously unknown variants identification for future targeted studies.

Finally, we can guide you through your whole exome sequencing journey with 22,000 genes and clinical exome sequencing capabilities with 6,000 genes, including SNPs, CNVs, and indels.

B-cell Receptor Sequencing

BCR sequencing explores the diversity of the B-cell receptor repertoire through sequencing. Cerba Research is committed to providing comprehensive solutions with the best quality to advance your global cell therapy trial. We already have experience with already existing and validated kits for your BCR sequencing needs.


Analysis of the genes coding for the 16S ribosomal RNA for bacterial identification and the ITS region for the characterization of fungal species.

Other applications available

  • Genotyping (Massarray)
    • CGH array
    • HLA Typing
    • PGx
    • And more…

Discover the Benefits of Our Genomics Services

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and see how we can help advance your research

Contact Us